Bile acids affect the growth of human cholangiocarcinoma via NF-kB pathway

Cancer Investigation

Volumn 31, Issue 2, 2013, Pages 111-120

  Dai, Jiaqi ^a   Wang, Hongxia ^a   Dong, Ying ^a   Zhang, Yinxin ^a   Wang, Jian ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Bile Acids; COX 2; Human Cholangiocarcinoma; IL 6; NF kB

Indexed keywords

CHENODEOXYCHOLIC ACID; CYCLOOXYGENASE 2; DEOXYCHOLIC ACID; GLYCOCHENODEOXYCHOLIC ACID; GLYCOCHOLIC ACID; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6;

ANIMAL TISSUE; APOPTOSIS; ARTICLE; BILE DUCT CARCINOMA; CELL GROWTH; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GROWTH; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; UPREGULATION; WESTERN BLOTTING;

ANIMALS; BILE ACIDS AND SALTS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL SURVIVAL; CHOLANGIOCARCINOMA; CYCLOOXYGENASE 2; DISEASE MODELS, ANIMAL; HUMANS; I-KAPPA B PROTEINS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-6; MICE; MICE, NUDE; NF-KAPPA B; PHOSPHORYLATION; RANDOM ALLOCATION; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84873103946     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2012.762781     Document Type: Article

References (43)

1. Patel T. Worldwide trends in mortality from biliary tract malignancies. BMC Cancer 2002;2:10.
2. Stefania Mosconi, Giordano D Beretta, Roberto Labianca, et al. Cholangiocarcinoma. Oncology/Hematology 2009;69:259-270.
3. Trauner M, Fickert P, Halilbasic E, et al. Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases.Wien MedWochenschr 2008;158:542-548.
4. BurnatG,RauT, ElshimiE, et al. Bile acids induce overexpression of homeobox gene CDX-2 and vascular endothelial growth factor (VEGF) in human Barrett's esophageal mucosa and adenocarcinoma cell line. Scand J Gastroenterology 2007;42:1460-1465.
5. Schramm G, Surmann EM, Wiesberg S, et al. Analyzing the regulation of metabolic pathways in human breast cancer. BMCMed Genomics 2010;3:39.
6. Bernstein H, Bernstein C, Payne CM, et al. Bile acids as endogenous etiologic agents in gastrointestinal cancer.World J Gastroenterology 2009;15:3329-3340.
7. Debruyne PR, Brunel EA, Karaguni IM, et al. Bile acids stimulate invasion and haptotaxis in human colorectal cancer cells through activation of multiple oncogenic signaling pathways. Oncogene 2002;21:6740-6750. (Pubitemid 35221916)
8. Park MJ, Kim KH, Kim HY, et al. Bile acid induces expression of COX-2 through the homeodomain transcription factor CDX1 and orphan nuclear receptor SHP in human gastric cancer cells. Carcinogenesis 2008;29:2385-2393.
9. Jiaqi Dai, Hongxia Wang, Yihui Shi, et al. Impact of bile acids on the growth of human cholangiocarcinoma via FXR. JHO 2011;4:41.
10. Wang YD, Chen WD, Wang M, et al. Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response. Hepatology 2008; 48:1632-1643.
11. Raza SA, Clifford GM, Franceschi S. Worldwide variation in the relative importance of hepatitis B and hepatitis C viruses in hepatocellular carcinoma: a systematic review. Br J Cancer 2007;96:1127-1134. (Pubitemid 46608308)
12. Jens J. W. Tischendorf, Andreas Geier, Christian Trautwein. Current diagnosis and management of primary sclerosing cholangitis. Liver Transplantation 2008;4:735-746. (Pubitemid 351895502)
13. Gu X, Ke S, Liu D, et al. Role of NF-kappaB in regulation of PXRmediated gene expression: a mechanism for the suppression of cytochrome P-450 3A4 by proinflammatory agents. J Biol Chem 2006;281:17882-17889. (Pubitemid 44035587)
14. Ghosh S, Kann M. Missing pieces in the NF-kappa puzzle. Cell 2002;109(supp1):81-96.
15. Balk F,Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539-545. (Pubitemid 32173595)
16. Aggarwal BB. Nuclear factor-kappaB: the enemy within Cancer. Cell 2004;6(3):203-208. (Pubitemid 39222032)
17. Wehbe H, Henson R, Meng F, et a1. Interleukin-6 contributes to growth in cholangiocarcinoma cells by aberrant promoter methylation and gene expression. Cancer Res 2006;66:10517-10524. (Pubitemid 44799774)
18. Isomoto H. Epigenetic alterations in cholangiocarcinomasustained IL-6/STAT3 signaling in cholangiocarcinoma due to SOCS3 epigenetic silencing. Digestion 2009;1:2-8.
19. Carmichael J, DeGraff WG, Gazdar AF, et al. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 1987;47:936-392.
20. Wang J, Shi YQ, Yi J, et al. Suppression of growth of pancreatic cancer cell and expression of vascular endothelial growth factor by gene silencing with RNA interference. J Dig Dis 2008;9: 228-237.
21. Swales KE, Korbonits M, Carpenter R, et al. The farnesoid X receptor is expressed in breast cancer and regulates apoptosis and aromatase expression. Cancer Res 2006;66:10120-10126. (Pubitemid 44672066)
22. Blechacz B, Gores GJ. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology 2008;48: 308-321. (Pubitemid 351975555)
23. Khan SA,Thomas HC, Davidson BR, et al. Cholangiocarcinoma. Lancet 2005;366:1303-1314. (Pubitemid 41416587)
24. Fava G, Marzioni M, Benedetti A, et al. Molecular pathology of biliary tract cancers. Cancer Lett 2007;250:155-167. (Pubitemid 46529440)
25. Lamireau T, Zoltowska M, Levy E, et al. Effects of bile acids on biliary epithelial cells: proliferation, cytotoxicity, and cytokine secretion. Life Sci 2003;72:1401-1411. (Pubitemid 36090124)
26. Horowitz NS,Hua J, PowellMA, et al.Novel cytotoxic agents from an unexpected source: bile acids and ovarian tumor apoptosis.Gynecol Oncol 2007;107:344-349. (Pubitemid 47575739)
27. Baker PR, Wilton JC, Jones CE, et al. Bile acids influence the growth, oestrogen receptor and oestrogen-regulated proteins of MCF-7 human breast cancer cells. Br J Cancer 1992;65: 566-572.
28. WerneburgNW, Yoon JH,HiguchiH,Gores GJ. Bile acids activate EGF receptor via a TGF-alpha-dependent mechanism in human cholangiocyte cell lines. Am J Physiol Gastrointest Liver Physiol. 2003;285(1):G31-6. (Pubitemid 36736385)
29. Suzuki S, Hashizume K. Do PPARgamma ligands suppress the growth of cholangiocarcinoma or the cholangiohepatitis induced by the tumor? PPAR Res 2008; 2008:587401.
30. Beg AA, ShaWC, Bronson RT, et a1. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B. Nature 1995;376(6536):167-170.
31. Wang YD, Chen WD, Wang M, et al. Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response. Hepatology 2008;48:1632-1643.
32. Lin MT, Zuon CY, Chang CC, et al. Cyr61 induces gastric cancer cell motility/invasion via activation of the integrin/nuclear factor-kappaB/ cyclooxygenase-2 signaling pathway. Clin Cancer Res 2005;11:5809-5820.
33. Glinghammar B, Inoue H, Rafter JJ.Deoxycholic acid causesDNA damage in colonic cells with subsequent induction of caspases, COX-2 promoter activity and the transcription factors NF-kB and AP-1. Carcinogenesis 2002;23:839-845. (Pubitemid 34567524)
34. Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005;5:749-759. (Pubitemid 41400849)
35. Calmus Y, Guechot J, Podevin P, et al. Differential effects of chenodeoxycholic and ursodeoxycholic acids on interleukin 1, interleukin 6 and tumor necrosis factor-alpha production by monocytes. Hepatology 1992;16:719-723.
36. Dvorak K, Chavarria M, Payne CM, et al. Activation of the interleukin-6/STAT3 antiapoptotic pathway in esophageal cells by bile acids and low pH: relevance to barrett's esophagus. Clin Cancer Res 2007;13:5305-5313. (Pubitemid 47510354)
37. Wehbe H, Henson R, Meng F, et a1. Interleukin-6 contributes to growth in cholangiocarcinoma cells by aberrant promoter methylation and gene expression. Cancer Res 2006;66:10517-10524. (Pubitemid 44799774)
38. Meng F, Yamagiwa Y, Ueno Y, et a1. Over-expression of intexleukin-6 enhances cellsurvival and transformed cell growth in human malignant cholangiocytes. J Hepatol 2006;44: 1055-1065. (Pubitemid 44308229)
39. Isomoto H. Epigenetic alterations in cholangiocarcinomasustained IL-6/STAT3 signaling in cholangiocarcinoma due to SOCS3 epigenetic silencing. Digestion 2009;1:2-8.
40. Yamagiwa Y,Meng F, Patel T. Interleukin-6 decreases senescence and increases telomerase activity in malignant human cholangiocytes. Life Sci 2006;78(21);2494-2502.
41. M?uhlbauer M, Allard B, BosserhoffAK, et al.Differential effects of deoxycholic acid and taurodeoxycholic acid on NF-kappa B signal transduction and IL-8 gene expression in colonic epithelial cells. Am J Physiol Gastrointest Liver Physiol 2004;286(6):G1000-1008. (Pubitemid 38715663)
42. Yoon JH, Higuchi H, Werneburg NW, et al. Bile acids induce cycooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line.Gastroenterology 2002;122(4):985-993.
43. Yoon JH, Canbay AE, Werneburg NW, et al. Oxysterols induce cyclooxygenase-2 expression in cholangiocytes: Implications for biliary tract carcinogenesis. Hepatology 2004;39(3):732-738. (Pubitemid 38337652)